glp 1 agonists and sglt2 inhibitors combination Diabetic Agents, From Metformin to GLP1 Receptor Agonists: JACC Focus Seminar SGLT-2 Inhibitors and GLP-1 Agonists:
Description
Diabetes and Metabolism

D., Dashi G., Maslov I., et al., Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales, Frontiers in Pharmacology 12 (2022): 12, 10.3389/fphar.2021.807548

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early alzheimers disease with lecanemab, an anti-abeta protofibril antibody

Beyond tirzepatide and retatrutide, Eli Lilly is also investing in oral GLP-1 therapies ( orforglipron ), aiming to provide convenient, effective alternatives to injections

GLP-1s may not be suitable for everyone

Cellular and molecular mechanisms of metformin: an overview
